论文部分内容阅读
目的探讨硼替佐米联合地塞米松治疗多发性骨髓瘤(MM)的疗效。方法将2009年1月-2013年1月我院42例MM患者随机分为两组,试验组20例给予硼替佐米联合地塞米松治疗,对照组22例给予传统方案治疗,观察两组临床疗效、不良反应及治疗满意度。结果试验组临床有效率高于对照组,不良反应发生率低于对照组,治疗满意率高于对照组(P<0.05)。结论硼替佐米联合地塞米松治疗MM疗效显著,可有效控制病情进展,不良反应发生率较低,值得临床推广。
Objective To investigate the efficacy of bortezomib combined with dexamethasone in the treatment of multiple myeloma (MM). Methods From January 2009 to January 2013, 42 patients with MM in our hospital were randomly divided into two groups. 20 patients in the experimental group were treated with bortezomib plus dexamethasone, while 22 patients in the control group were treated with conventional therapy. The clinical outcomes of two groups Efficacy, adverse reactions and treatment satisfaction. Results The clinical effective rate of the experimental group was higher than that of the control group, the incidence of adverse reactions was lower than that of the control group, and the satisfaction rate of treatment was higher than that of the control group (P <0.05). Conclusion Bortezomib and dexamethasone treatment of MM significant effect, which can effectively control the progression of the disease, the incidence of adverse reactions is low, worthy of clinical promotion.